Key Points
- CFO Michael Kaseta sold 18,938 Liquidia shares at an average price of $28.48, generating $539,354. The sale occurred under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 340,148 shares.
- Liquidia’s stock opened at $26.81 and has declined 3.1%, with a market capitalization of approximately $2.4 billion. Its latest quarterly results included $171.68 million in revenue, up 1,842.1% year over year, but earnings per share of $0.74 missed estimates by $0.02.
- Analyst sentiment remains mixed, with a consensus rating of “Hold” and an average price target of $83.69. Ratings range from “Strong Sell” to “Strong Buy,” while individual targets span $30 to $130.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Sanjeev Khindri sold 1,101 shares of the business's stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $31,356.48. Following the sale, the insider owned 64,846 shares of the company's stock, valued at approximately $1,846,814.08. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Liquidia Trading Down 3.1%
Shares of LQDA stock opened at $26.81 on Wednesday. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The firm has a fifty day moving average price of $63.40 and a 200-day moving average price of $61.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analysts' expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company's revenue was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.49) earnings per share. As a group, equities analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.
Wall Street Analysts Forecast Growth
LQDA has been the subject of a number of research reports. Wells Fargo & Company reissued an "equal weight" rating and set a $30.00 price target (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. Stephens set a $130.00 price objective on Liquidia in a research note on Friday, July 24th. Wall Street Zen cut Liquidia from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Citigroup reaffirmed a "neutral" rating on shares of Liquidia in a report on Thursday, October 1st. Finally, Zacks Research downgraded Liquidia from a "hold" rating to a "strong sell" rating in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $83.69.
Check Out Our Latest Stock Report on LQDA
Liquidia News Summary
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
- Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
- Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
- Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
- Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
- Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week
Hedge Funds Weigh In On Liquidia
A number of institutional investors have recently modified their holdings of the stock. WINTON GROUP Ltd bought a new stake in Liquidia during the 2nd quarter valued at $335,000. Arizona State Retirement System grew its position in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company's stock worth $1,405,000 after buying an additional 900 shares in the last quarter. Nykredit A S bought a new position in shares of Liquidia during the 2nd quarter worth $177,000. Corient Private Wealth LP bought a new position in shares of Liquidia during the 2nd quarter worth $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Liquidia during the second quarter valued at $1,236,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
About Liquidia
(
Get Free Report)
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.
Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
